News zum Sektor Gesundheit aus Hong Kong (China)

 

SIMCERE PHARMA (02096.HK) announced that it repurchased 1.598 million shares on October 9 at prices ranging from HKD10.66 to HKD11.003 per share, involving approximately HKD17.3699 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the......

[The content of this article has been produced by our advertising partner.] As DBS Hong Kong and Manulife Hong Kong celebrate the 10th anniversary of their bancassurance partnership, the two organizations are marking the milestone with a HK$1 million donation to Oasis – Centre for Personal Growth & Crisis Intervention, a centre under the Hospital Authority's Corporate Clinical Psychology Services. The milestone also reflects a decade of collaboration in helping customers protect their wealth and......

Trader Alexander Albicker alias MrTecDAX über sein wikifolio "Dirty Money" ( https://go.brn-ag.de/558 ), das bewusst eine Gegenposition zu ESG- und SRI-Anlagen (Socially Responsible Investment) bilden soll und auf aus seiner Sicht kontroverse oder unterbewertete Aktien setzt. Als Beispiele aus 49 Werten nennt er im Rahmen des Züricher Börsentages Glencore, Bayer, Shell und Tsakos Energy Navigation und erläutert, warum er diese Titel als "dirty" oder sogar "fragwürdig", aber eben doch auch attraktiv einstuft. "Wenn irgendetwas legal ist, der Staat es nicht verbietet und es an Börsen gehandelt wird, dann wäre es hier in meinem wikifolio. Wenn eine Aktie aber zu sustainable wird, fliegt sie unter Umständen raus."...

CSPC PHARMA (01093.HK) announced that positive results from the Phase III clinical study of the glucagon-like peptide-1 (GLP-1) receptor agonist ecnoglutide alpha injection (TG103 injection), developed by the group, in combination with metformin for the treatment of Chinese adult patients with type 2 diabetes mellitus (T2DM), we......

Hong Kong can attract more global biotech investments if the city builds up a new healthcare financial model, according to AstraZeneca, a Cambridge-based multinational pharmaceutical giant. While global drug makers have been doubling down on investments in mainland China in recent years, AstraZeneca brought over 60 clinical trials to the city and invested over HK$200 million (US$25.5 million) over the past three years. Hong Kong was still a key research and development hub for the firm, David......

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

The HSI closed at 24,613, up 89 pts or 0.37%, with full-day turnover reaching HKD187.158 billion. The HSTECH closed at 4,253, up 4 pts or 0.1%. The HSCEI closed at 8,220, up 41 pts or 0.5%.Among major dotcoms, MEITUAN-W (03690.HK) rose 1.77%; KUAISHOU-W (01024.HK) gained 2.32%; BIDU-W (09888.HK) and JD-SW (09618.HK) climbed more......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Here are some of the companies making headlines in midday trading....

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

CSPC PHARMA (01093.HK) announced that the SYS 6077 injection developed by the group has obtained approval from the National Medical Products Administration of China for the issuance of a clinical trial approval notice, allowing clinical trials to be conducted in China. The approved clinical indication is advanced malignant tumor......

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first three participants have all received their first dose of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial....

CSPC PHARMA (01093.HK) announced that the Phase III clinical trial of Becotatug (JMT101) in combination with osimertinib as a first-line treatment for locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations achieved its primary endpoint in a pre-specified interim analysis, delivering posit......

CSPC PHARMA (01093.HK) announced that the Phase III clinical trial in China for docetaxel for injection (albumin-bound) (HB1801), used for the treatment of advanced breast cancer, has recently been officially launched at the first research center in China. The clinical trial aims to evaluate the efficacy and safety of HB1801 com......